mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.Ker Yu, J J Gibbons|Endocrine Related Cancer|2001Cited by 418
Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteinesLourdes Toral‐Barza, Ker Yu|Molecular Cancer Therapeutics|2007Cited by 58
mTOR complex-2 stimulates acetyl-CoA and <i>de novo</i> lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancerYaqing Chen, Ker Yu|Oncotarget|2016Cited by 47
Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancersQingrou Li, Ker Yu|Acta Pharmacologica Sinica|2018Cited by 42